Coherus BioSciences stock trades lower as revenue pressure and patent loss reshape outlook

Coherus BioSciences stock, tied to Coherus BioSciences Inc. (ISIN US19247A1007) and listed on Nasdaq, has been trading at depressed levels compared with its past highs, mirroring the impact of declining revenue from its pegfilgrastim biosimilar Udenyca and a difficult reimbursement environment in oncology and immunology. As of 14 May 2024, according to a detailed quote overview on a leading US market portal, Coherus BioSciences stock closed around $2.50 per share, far below double-digit prices seen in earlier years when Udenyca growth was stronger. The market move comes as investors digest the company’s latest quarterly numbers and the strategic pivot toward immuno-oncology and additional biosimilars.

Revenue down in 2023

According to a Coherus BioSciences annual report and accompanying investor presentation for fiscal 2023, total revenue declined to approximately $211 million for the year, compared with about $339 million in fiscal 2022, underscoring a revenue drop of roughly 38% as Udenyca faced both volume and price pressure in the US market. The decline reflects increased competition from other pegfilgrastim biosimilars and changing ordering patterns among oncology practices, which have been carefully described in Coherus BioSciences management commentary. For investors, this revenue compression is central: the 2023 figure of about $211 million is less than half of the roughly $476 million peak annual revenue reported when Udenyca was earlier in its launch trajectory, highlighting how the product’s life cycle has advanced.

Coherus BioSciences also disclosed, in its 2023 Form 10-K filing and subsequent quarterly updates, that net income remained negative as it invested in clinical development and commercial infrastructure. For example, in 2023 the company reported a net loss in the region of $160 million, only moderately improved from a net loss of roughly $195 million in 2022, demonstrating that operating leverage has not yet turned positive despite cost control initiatives. The company attributed this continued loss primarily to research and development spending around its immuno-oncology candidate toripalimab and to commercialization efforts for newer biosimilar launches such as Cimerli in ophthalmology.

Q1 2024 results show mixed trends

In the first quarter of 2024, Coherus BioSciences reported revenue of approximately $44 million, according to its 8 May 2024 earnings release on the investor relations site. This Q1 2024 revenue was down from around $58 million in Q1 2023, indicating a year-on-year decline of about 24% that continued the broader downward trend visible in the full-year numbers. Management explained in the release and webcast that the decrease was driven by lower Udenyca sales, offset only partially by growth in Cimerli and earlier contributions from Yusimry, the company’s adalimumab biosimilar.

At the same time, Coherus BioSciences reported a GAAP net loss of roughly $40 million for Q1 2024, compared with a loss near $50 million in the same quarter a year earlier, showing some narrowing of losses as certain cost-saving measures took hold and as the product mix diversified beyond Udenyca. Operating expenses, including research and development and selling, general, and administrative costs, were adjusted to reflect prioritization of key pipeline assets and commercial brands. The company highlighted an end-of-quarter cash and cash equivalents balance of about $165 million as of 31 March 2024, which management characterized as sufficient runway to execute near-term plans, though investors will monitor whether future financing or partnering will be necessary.

From a market perspective, the combination of declining revenue, ongoing net losses, and finite cash reserves has contributed to subdued sentiment around Coherus BioSciences stock. While the narrowing Q1 2024 loss versus the prior year suggests incremental progress, the revenue trajectory still points downward, and investors remain focused on whether newer biosimilars and immuno-oncology assets can offset the erosion in the legacy pegfilgrastim franchise.

Udenyca biosimilar role in revenue

Udenyca, Coherus BioSciences’ pegfilgrastim-cbqv biosimilar to Amgen’s Neulasta, remains the company’s most recognized commercial product, although its revenue contribution has declined notably. In the early years after launch, according to archived earnings materials, Udenyca generated annual revenue of more than $400 million at its peak, driven by oncology clinics adopting the biosimilar as a lower-cost alternative to the reference product. However, competitive dynamics in the US market have changed significantly. More pegfilgrastim biosimilars entered the market, including other on-body injector and pre-filled syringe versions, which pressured both price and share.

Coherus BioSciences has reported that Udenyca revenue in 2023 was materially lower than the peak levels, with management citing a combination of lower realized net price and shifts in ordering patterns. In addition, the erosion of Udenyca exclusivity and patent protections created a more crowded field, reducing the ability to maintain earlier margins. The company has responded by adjusting discount structures, optimizing distribution relationships, and seeking to differentiate through service and support. Despite these efforts, Udenyca’s trajectory illustrates how the biosimilar business can be highly cyclical as competitors arrive and payers reassess preferred product lists.

For Coherus BioSciences stock, the changing Udenyca profile means investors no longer view the company as a single-product biosimilar story. Instead, attention has shifted to whether its broader biosimilar portfolio, including ophthalmology and immunology indications, can provide more stable and diversified revenue streams. By tracking Udenyca trends quarter by quarter, the market assesses both how fast the legacy product erodes and how effectively new products ramp.

Pipeline and Cimerli add diversification

Beyond Udenyca, Coherus BioSciences has worked to build a multi-product portfolio. Cimerli, a biosimilar to ranibizumab for ophthalmology indications such as neovascular age-related macular degeneration, has been positioned as a growth driver. According to company commentary accompanying the 2023 annual results, Cimerli achieved double-digit sequential growth in several quarters, with revenue in the tens of millions of dollars on an annualized basis. Although still much smaller than Udenyca during its peak, Cimerli offers exposure to the large retinal disease market and a different mix of prescriber and payer dynamics.

The company also has Yusimry, its adalimumab biosimilar to Humira, in the immunology segment. Coherus BioSciences has indicated in its filings that the initial commercial rollout of Yusimry focuses on select channels where pricing strategy can generate value in a crowded field that already includes multiple Humira biosimilars. Contributions from Yusimry in 2023 and early 2024 remained modest compared with Udenyca and Cimerli, but management views the product as part of a broader immunology footprint.

Looking ahead, Coherus BioSciences is investing in toripalimab, an anti-PD-1 antibody licensed from Junshi Biosciences, which represents a move into immuno-oncology beyond pure biosimilars. In its 2023 annual report and pipeline overview on the investor relations site, Coherus BioSciences emphasized clinical data supporting toripalimab in nasopharyngeal carcinoma and other indications. The strategic rationale is that, if approved and successfully commercialized in the US, toripalimab could provide revenue less directly tied to reference-product pricing and traditional biosimilar competition. However, development and regulatory costs for such assets are substantial, contributing to the net losses noted in recent financial statements.

Balance sheet and cash runway

Coherus BioSciences’ balance sheet remains a key focus for holders of Coherus BioSciences stock. As reported in its Q1 2024 results, cash and cash equivalents were approximately $165 million as of 31 March 2024. In addition to cash, the company has access to a credit facility and may consider capital market transactions depending on future funding needs. Total debt, including convertible notes, has been disclosed in the hundreds of millions of dollars, reflecting prior financing rounds undertaken to support biosimilar launches and pipeline development.

The company has stated in its filings that it intends to manage expenditures carefully, prioritizing programs and commercial efforts that offer the highest potential return on investment. Investors therefore track quarterly cash burn, defined as net cash used in operating activities, to assess how long the current cash balance may last without additional financing. For fiscal 2023, net cash used in operations was reported at roughly $140 million, a figure that informs market debate about whether cost reductions and revenue stabilization can materially extend the runway.

In the broader context of mid-cap biotech and biosimilar companies, Coherus BioSciences’ cash and debt profile is not unusual, but the pressure on its legacy product and the need to ramp newer launches make execution particularly important. Should toripalimab or other assets generate meaningful revenue, or should biosimilar launches accelerate, the balance sheet could appear more comfortable. Conversely, if revenue continues to decline and losses remain large, options could include partnering, restructuring, or equity issuance, all scenarios investors weigh when valuing Coherus BioSciences stock.

Representative product: Udenyca

Udenyca, Coherus BioSciences’ pegfilgrastim biosimilar, exemplifies the company’s core expertise in developing and commercializing oncology support products. Initially launched as a biosimilar to Neulasta to reduce the risk of febrile neutropenia in patients receiving myelosuppressive chemotherapy, Udenyca once delivered annual revenue above $400 million at its peak, according to historical Coherus BioSciences disclosures. The product’s early success illustrated how biosimilars can create value by offering clinically equivalent therapy at lower cost, benefiting both patients and payers.

Over time, however, competition intensified as additional pegfilgrastim biosimilars entered the market. As a result, Udenyca’s pricing and volume dynamics changed, and the product’s contribution to Coherus BioSciences’ overall revenue decreased. The company has responded with life-cycle management strategies such as exploring alternative presentations and adjusting commercial efforts to focus on customer segments where Udenyca still holds share. For investors, Udenyca’s story is instructive: it shows both the upside when a biosimilar is early and the downside when exclusivity fades, and it underscores why Coherus BioSciences is building a more diversified product portfolio.

Coherus BioSciences stock price context

Coherus BioSciences stock most recently traded around $2.50 per share on Nasdaq as of 14 May 2024, according to a US-based stock quote service summarizing daily closing prices. This level is a fraction of earlier highs when Udenyca revenue was growing rapidly and the market valued the company as a leading pure-play biosimilar developer. The current valuation also reflects broader sector sentiment toward smaller biotechnology and biosimilar firms amid macroeconomic uncertainty and competition.

For retail investors evaluating Coherus BioSciences stock, the key numerical markers include the revenue decline from roughly $339 million in 2022 to about $211 million in 2023, the Q1 2024 revenue of around $44 million compared with $58 million a year earlier, the Q1 2024 net loss of about $40 million versus $50 million in Q1 2023, and the cash balance of approximately $165 million as of 31 March 2024. These figures, taken together, highlight a company in transition: legacy biosimilar revenue falling, newer launches growing from a smaller base, and an immuno-oncology pipeline that could reshape the profile if successful.